[
  {
    "ts": null,
    "headline": "RBC Sees Johnson & Johnson (JNJ) Well Positioned to Manage Legal Overhang",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Wide Moat Dividend Stocks to Invest in. On February 3, RBC Capital raised its price target on Johnson & Johnson (NYSE:JNJ) to $255 from $240 and reiterated an Outperform rating. The firm said the company is unlikely to reverse the core implications of the Daubert […]",
    "url": "https://finnhub.io/api/news?id=69c207d92c6bdf9668978c2db8bf9af2efaa57a41ee62811c68e03fcc0dab89b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770320542,
      "headline": "RBC Sees Johnson & Johnson (JNJ) Well Positioned to Manage Legal Overhang",
      "id": 138367484,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Wide Moat Dividend Stocks to Invest in. On February 3, RBC Capital raised its price target on Johnson & Johnson (NYSE:JNJ) to $255 from $240 and reiterated an Outperform rating. The firm said the company is unlikely to reverse the core implications of the Daubert […]",
      "url": "https://finnhub.io/api/news?id=69c207d92c6bdf9668978c2db8bf9af2efaa57a41ee62811c68e03fcc0dab89b"
    }
  },
  {
    "ts": null,
    "headline": "Is Johnson & Johnson (JNJ) Pricing Reflect Recent Healthcare Portfolio Focus?",
    "summary": "If you have been wondering whether Johnson & Johnson is fairly priced or offering value right now, this article will walk through what the numbers are actually saying about the stock. The share price last closed at US$234.47, with returns of 3.0% over 7 days, 14.8% over 30 days, 13.1% year to date, 56.2% over 1 year and 57.0% over 3 years. These performance figures may influence how investors think about both upside potential and risk. Recent news around Johnson & Johnson has focused on its...",
    "url": "https://finnhub.io/api/news?id=2c3df316cc26e894b2c858be044123be96a181a5519cad571a16ce7319a50277",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770311616,
      "headline": "Is Johnson & Johnson (JNJ) Pricing Reflect Recent Healthcare Portfolio Focus?",
      "id": 138366080,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "If you have been wondering whether Johnson & Johnson is fairly priced or offering value right now, this article will walk through what the numbers are actually saying about the stock. The share price last closed at US$234.47, with returns of 3.0% over 7 days, 14.8% over 30 days, 13.1% year to date, 56.2% over 1 year and 57.0% over 3 years. These performance figures may influence how investors think about both upside potential and risk. Recent news around Johnson & Johnson has focused on its...",
      "url": "https://finnhub.io/api/news?id=2c3df316cc26e894b2c858be044123be96a181a5519cad571a16ce7319a50277"
    }
  },
  {
    "ts": null,
    "headline": "Why Mid Cap Dividend Stocks Are Gaining an Edge Over Large Caps This Year",
    "summary": "Large-cap dividend stocks have dominated portfolios for years and for understandable reasons. Names like Johnson & Johnson (NYSE:JNJ), Procter & Gamble (NYSE:PG), and Coca-Cola (NYSE:KO) have all offered stability, brand recognition, and decades of dividend growth. Giving you a safe feeling, especially when the market turned against you, these giants held their ground even as ... Why Mid Cap Dividend Stocks Are Gaining an Edge Over Large Caps This Year",
    "url": "https://finnhub.io/api/news?id=42a4c9ff9ecad47c9258d12ad07a60061a1d4b4cf8043fd64072157dab2bd19a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770308093,
      "headline": "Why Mid Cap Dividend Stocks Are Gaining an Edge Over Large Caps This Year",
      "id": 138366081,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Large-cap dividend stocks have dominated portfolios for years and for understandable reasons. Names like Johnson & Johnson (NYSE:JNJ), Procter & Gamble (NYSE:PG), and Coca-Cola (NYSE:KO) have all offered stability, brand recognition, and decades of dividend growth. Giving you a safe feeling, especially when the market turned against you, these giants held their ground even as ... Why Mid Cap Dividend Stocks Are Gaining an Edge Over Large Caps This Year",
      "url": "https://finnhub.io/api/news?id=42a4c9ff9ecad47c9258d12ad07a60061a1d4b4cf8043fd64072157dab2bd19a"
    }
  },
  {
    "ts": null,
    "headline": "This Medical Technology Leader Sees Growth Into The 2040s",
    "summary": "Medical technology leader Halozyme Therapeutics is this week's IBD Sector Leaders selection, having bypassed two buy points and entered a buy zone. The recent IBD Stock Of The Day is rallying after the company raised its 2025 and 2026 outlook.",
    "url": "https://finnhub.io/api/news?id=465458d7404af0b7fba7176e60fd2dabe65f7c5503d605c1316f76310d768b75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770303347,
      "headline": "This Medical Technology Leader Sees Growth Into The 2040s",
      "id": 138364445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Medical technology leader Halozyme Therapeutics is this week's IBD Sector Leaders selection, having bypassed two buy points and entered a buy zone. The recent IBD Stock Of The Day is rallying after the company raised its 2025 and 2026 outlook.",
      "url": "https://finnhub.io/api/news?id=465458d7404af0b7fba7176e60fd2dabe65f7c5503d605c1316f76310d768b75"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Named Inaugural Global Impact Award Winner by the Healthcare Businesswomen's Association (HBA)",
    "summary": "Johnson & Johnson has been named the inaugural recipient of the Global Impact Award by the Healthcare Businesswomen's Association (HBA), a global leadership accelerator, business growth partner, and enterprise solution for the healthcare and life sciences industries.",
    "url": "https://finnhub.io/api/news?id=f1e973cdb755b2f39e476f23b38311b5b3c6d411f7c4624c4b5b191eefcaf9d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770300000,
      "headline": "Johnson & Johnson Named Inaugural Global Impact Award Winner by the Healthcare Businesswomen's Association (HBA)",
      "id": 138364454,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson has been named the inaugural recipient of the Global Impact Award by the Healthcare Businesswomen's Association (HBA), a global leadership accelerator, business growth partner, and enterprise solution for the healthcare and life sciences industries.",
      "url": "https://finnhub.io/api/news?id=f1e973cdb755b2f39e476f23b38311b5b3c6d411f7c4624c4b5b191eefcaf9d0"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma CEOs set sights on massive growth in years to come",
    "summary": "The CEOs at Johnson & Johnson, Pfizer and Merck have big plans for future revenue even as they face difficult odds in the here and now.",
    "url": "https://finnhub.io/api/news?id=332f26e987f5d515a897b364ec918ce084a25c401a4509a3eb9a878473ef004b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770278400,
      "headline": "Big Pharma CEOs set sights on massive growth in years to come",
      "id": 138364455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The CEOs at Johnson & Johnson, Pfizer and Merck have big plans for future revenue even as they face difficult odds in the here and now.",
      "url": "https://finnhub.io/api/news?id=332f26e987f5d515a897b364ec918ce084a25c401a4509a3eb9a878473ef004b"
    }
  }
]